U.S. Platelet Rich Plasma Market 2025: Size, Share, & Industry Insights
The U.S. platelet-rich plasma market was valued at USD 117.2 million in 2022 and is expected to grow at a CAGR of 17.2% during the forecast period.
Platelet-rich plasma (PRP) therapy, a key component of regenerative medicine, is widely used to accelerate healing in injured ligaments, muscles, tendons, and joints. Its growing applications in sports injuries, cosmetics, and other fields have driven demand for PRP injections in the U.S. According to a 2023 Courier-Journal article, approximately 30 million children and teens participate in organized sports, with over 3.5 million injuries reported annually. Additionally, rising interest in aesthetics, ongoing research, and strategic initiatives by key industry players are further fueling market growth.
Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-platelet-rich-plasma-market-108787
List Of Key Companies Profiled In U.S. Platelet Rich Plasma Market:
· Arthrex, Inc. (U.S.)
· Zimmer Biomet (U.S.)
· Isto Biologics (U.S.)
· ThermoGenesis Holdings, Inc. (U.S.)
· Exactech, Inc. (U.S.)
· EmCyte Corporation (U.S.)
· Stryker (U.S.)
· Medical Devices Business Services, Inc. (Johnson & Johnson Services, Inc.) (U.S.)
· Terumo Corporation (Japan)
Driving Factors:
Expanding PRP Applications in Chronic Disorders Drive Market Growth
Platelet-rich plasma (PRP) therapy promotes healing and tissue regeneration, with broad applications in orthopedics, neurology, cosmetics, and wound care. The rising prevalence of chronic diseases and injuries is fueling demand across the U.S. Increasing PRP use in wound healing further boosts market growth, with conditions like diabetic foot ulcers affecting 2 million people annually, according to the Health Innovation Program (2020). Additionally, CDC data from 2021 reports that 58.5 million U.S. adults (23.7%) have arthritis, further driving the need for regenerative treatments.
Restraining Factors:
Regulatory Challenges and Side Effects May Hinder Market Growth
The growth of platelet-rich plasma (PRP) therapy faces challenges due to stringent regulatory standards and complexities in manufacturing and clinical use. Additionally, high costs and potential side effects, including blood clotting, allergic reactions, infections, and nerve injuries, may limit adoption. Treatment effectiveness varies, with some patients experiencing no improvement. According to the U.S. Center for Sports Medicine, not all athletes respond to PRP injections, and in some cases, pain and soreness persist or worsen, further restricting market expansion.
Market Segmentation:
By Product
The u.s. platelet rich plasma market is categorized into pure platelet-rich plasma (Pure PRP), leukocyte-rich platelet-rich plasma (L-PRP), platelet-rich fibrin (PRF), and others. In 2022, the Pure PRP segment held the largest market share, driven by its widespread use in healing, tissue repair, and regeneration. Strong R&D efforts and new product launches further fuel growth. For example, in July 2020, EmCyte Corporation received FDA approval for "PureBMC," a platelet and cell concentrating system, highlighting the increasing interest of manufacturers in advancing PRP technology.
By Application
The u.s. platelet rich plasma market is segmented into orthopedics, neurology, cosmetics, wound care, and others. The wound care segment dominated in 2022, as PRP injections have become more prevalent in treating wounds and injuries due to their high platelet concentration and growth factors that aid healing. According to a 2020 study by the Mayo Evidence-Based Practice Center (EPC), autologous PRP therapy demonstrated moderate evidence for improving wound closure and low evidence for reducing healing time in lower extremity diabetic ulcers.
By End User
The market is divided into hospitals & ASCs, specialty clinics, and others. In 2022, hospitals & ASCs accounted for the largest share, as patients with chronic and acute wounds prefer these settings for treatment due to skilled professionals, advanced care options, and adequate reimbursement policies. A 2022 Healio article citing a Diabetes Research and Clinical Practice study found that diabetic foot ulcer patients were nearly three times more likely to be hospitalized during treatment. The higher prevalence of complex wounds and favorable reimbursement policies continue to drive growth in this segment.
Key Industry Developments:
In June 2023, Isto Biologics introduced Precise, an innovative technology designed to deliver platelet-rich plasma (PRP) with accurately concentrated cellular fractions. This advanced product enables physicians and surgeons to customize PRP treatments based on individual patient needs.